Purchase Order 75N93020P01020

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Becton, Dickinson and Company (BD Biosciences) valued at $26,271.50 on April 20, 2020, for high parameter conjugates and HU CD197 antibody, with performance completed by April 19, 2021. Work is performed at Brea, California. This award was issued under the Coronavirus COVID-19 national interest action code and carries no small business set-aside.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Becton, Dickinson and Company (BD Biosciences) valued at $13,237.18 on October 19, 2020. Place of performance is Bethesda, Maryland. The order is firm fixed price with no small business set-aside. Ultimate completion date is January 20, 2021. The source does not specify the equipment or supplies purchased under this order.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Becton, Dickinson and Company (BD Biosciences) valued at $11,535.00 on July 29, 2020, for Human IL-4 (Clone MP4-25D2) BB700 antibody reagent, 1 milligram quantity. Performance location is San Jose, California. The order was completed on August 28, 2020. The award was designated under the Coronavirus COVID-19 National Interest Action Code.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Becton, Dickinson and Company (BD Biosciences) for $348,885.85 on September 17, 2020, with completion by November 27, 2020. The order covers a BD LSR Fortessa flow cytometer system for cell analysis equipment and examination of sample data. Performance occurs in San Jose, California. Pricing is firm fixed price with no small business set-aside.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Becton, Dickinson and Company on September 12, 2018, with a ceiling value of $195,435.87 and an ultimate completion date of March 29, 2019. The contract is firm fixed price with no set-aside used. Place of performance is San Jose, California. The originating pre-solicitation opportunity was posted August 28, 2018, with a due date of September 6, 2018.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Becton, Dickinson and Company (BD Biosciences) valued at $260,967.29 on June 15, 2020, for a BD FACSAria Fusion SO laser option upgrade in support of COVID-19 response efforts. Place of performance is San Jose, California. The order carries firm fixed pricing and was scheduled for completion by September 16, 2020. No small business set-aside was used.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Becton, Dickinson and Company (BD Biosciences) for $41,964.74 on July 21, 2015, for a flow cytometer. Performance is located in San Jose, California. The order carries a firm fixed price and an ultimate completion date of August 20, 2015. No set-aside was applied.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Becton, Dickinson and Company for BD cytometers and lasers valued at $34,936.89 on April 16, 2018, with completion on January 20, 2019. Performance occurs in Bethesda, Maryland. The order is firm fixed price with no set-aside applied.</p>

This $19,713 firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Becton, Dickinson and Company's IDS division, operating as BD Diagnostic Systems. The award is for the provision of 90 BD antibodies, a commercial item. The contract has no set-aside designation and is scheduled for completion on July 22, 2016. Becton, Dickinson is a major manufacturer of medical...

<p>The National Institute of Allergy and Infectious Diseases issued a $21,515 delivery order to Becton, Dickinson and Company (BD Biosciences) on March 28, 2018, for fluorescently conjugated monoclonal antibodies and flow cytometry consumables for the Vaccine Research Center.</p> <p>Place of performance is San Jose, California. The order is firm fixed price with an ultimate completion date of April 6, 2018. No set-aside was applied.</p>